Pharmacokinetics and Pharmacodynamics — MCQs

Pharmacokinetics and Pharmacodynamics Indian Medical PG Practice Questions and MCQs

Question 331: Which is the most common cytochrome P450 enzyme associated with drug metabolism?

A. CYP3A4/5 (Correct Answer)
B. CYP2D6
C. CYP2C8/9
D. CYP2C19

Explanation: **Explanation:** **1. Why CYP3A4/5 is the Correct Answer:** CYP3A4 is the most abundant and clinically significant cytochrome P450 isoform in humans. It accounts for approximately **30% of the total CYP content in the liver** and is responsible for the metabolism of nearly **50% of all clinically used drugs**. Its high expression in both the liver and the intestinal wall makes it a major determinant of first-pass metabolism and oral bioavailability. **2. Analysis of Incorrect Options:** * **CYP2D6 (Option B):** While it is the second most important enzyme and metabolizes about 25% of drugs (including beta-blockers, antidepressants, and opioids like codeine), it is highly **polymorphic**. It is not the most common by volume or total drug substrate count. * **CYP2C8/9 (Option C):** These metabolize roughly 15% of drugs. CYP2C9 is notable for metabolizing drugs with narrow therapeutic indices, such as **Warfarin** and **Phenytoin**. * **CYP2C19 (Option D):** This enzyme metabolizes about 5% of drugs, including **Clopidogrel** (a prodrug) and Proton Pump Inhibitors (PPIs). **3. High-Yield Clinical Pearls for NEET-PG:** * **Inducers of CYP3A4:** Rifampicin, Phenytoin, Carbamazepine, St. John’s Wort (Mnemonic: **GPRS Cell Phone** - Griseofulvin, Phenytoin, Rifampicin, Smoking, Carbamazepine, Phenobarbitone). * **Inhibitors of CYP3A4:** Ketoconazole, Erythromycin, **Grapefruit juice**, Ritonavir (Mnemonic: **VITAMIN K** - Valproate, Isoniazid, Troleandomycin, Amiodarone, Macrolides, Itraconazole, NNRTIs, Ketoconazole). * **Suicide Inhibitor:** Grapefruit juice irreversibly inhibits CYP3A4 in the intestinal wall. * **Genetic Polymorphism:** Most commonly associated with **CYP2D6** (Poor vs. Ultra-rapid metabolizers) and **CYP2C19**.

Question 332: Which of the following drugs does not cross the placenta?

A. Heparin (Correct Answer)
B. Warfarin
C. Dicoumarol
D. Nicoumalone

Explanation: **Explanation:** The passage of drugs across the placental barrier is primarily determined by the drug's molecular weight, lipid solubility, and ionization state. **Why Heparin is the Correct Answer:** Heparin is a large, highly polar (negatively charged) polysaccharide molecule with a high molecular weight (approx. 15,000 Daltons). Due to its **large size and high degree of ionization**, it cannot cross the placental barrier. Consequently, heparin does not affect the fetus and is the **anticoagulant of choice during pregnancy**. **Why the Other Options are Incorrect:** * **Warfarin (Option B):** Unlike heparin, warfarin is a small, lipid-soluble molecule that easily crosses the placenta. It is highly teratogenic, especially during the first trimester, causing **Fetal Warfarin Syndrome** (characterized by nasal hypoplasia and stippled epiphyses). * **Dicoumarol (Option C) and Nicoumalone (Option D):** These are coumarin derivatives similar to warfarin. They are small molecules that cross the placenta and carry significant risks of fetal hemorrhage and teratogenicity. **NEET-PG High-Yield Pearls:** 1. **Rule of Thumb:** Drugs with a molecular weight **>1000 Daltons** generally do not cross the placenta. Heparin fits this criterion. 2. **LMWH (Low Molecular Weight Heparin):** Even though it is smaller than Unfractionated Heparin, LMWH (e.g., Enoxaparin) also **does not cross the placenta** and is frequently used in clinical practice for pregnant patients. 3. **Teratogenicity:** Warfarin is contraindicated in pregnancy (Category X), except in specific cases of high-risk mechanical heart valves, though even then, it is avoided near term due to the risk of intracranial hemorrhage during delivery.

Question 333: What is the mechanism of action of sildenafil?

A. Inhibits PDE 2
B. Inhibits PDE 4
C. Inhibits PDE 5 (Correct Answer)
D. Inhibits PDE 3

Explanation: **Explanation:** **Correct Answer: C. Inhibits PDE 5** Sildenafil is a selective inhibitor of **Phosphodiesterase-5 (PDE-5)**. In the vascular smooth muscle of the corpus cavernosum and pulmonary vasculature, Nitric Oxide (NO) activates guanylyl cyclase, which increases levels of **cyclic GMP (cGMP)**. PDE-5 is the enzyme responsible for the degradation of cGMP. By inhibiting PDE-5, sildenafil prevents the breakdown of cGMP, leading to prolonged smooth muscle relaxation and vasodilation. This results in increased blood flow to the penis (treating erectile dysfunction) and decreased pulmonary arterial pressure. **Why the other options are incorrect:** * **Option A (PDE-2):** PDE-2 inhibitors are primarily researched for cognitive enhancement and are not the target for sildenafil. * **Option B (PDE-4):** PDE-4 is mainly found in inflammatory cells. Inhibitors like **Roflumilast** are used in the treatment of COPD and severe asthma. * **Option D (PDE-3):** PDE-3 is found in cardiac muscle and blood vessels. Inhibitors like **Milrinone** and **Cilostazol** increase cAMP levels, acting as inotropes and vasodilators. **High-Yield Clinical Pearls for NEET-PG:** * **Indications:** Erectile dysfunction and Pulmonary Arterial Hypertension (PAH). * **Contraindication:** Never co-administer with **Nitrates** (e.g., Nitroglycerin) as it can cause life-threatening hypotension due to synergistic increases in cGMP. * **Side Effects:** Headache, flushing, and **Cyanopsia** (blue-tinted vision) due to weak cross-inhibition of PDE-6 in the retina. * **Tadalafil** is a similar drug with a much longer half-life (the "weekend pill").

Question 334: What is pharmacokinetics?

A. The study of drug movement in the body (Correct Answer)
B. The study of drug effects
C. The study of drug responses, governed by heredity
D. None of the above

Explanation: **Explanation:** **Pharmacokinetics** refers to the quantitative study of drug movement in, through, and out of the body. It essentially describes **"what the body does to the drug."** This process is governed by the **ADME** acronym: * **A**bsorption (entry into the blood) * **D**istribution (movement into tissues) * **M**etabolism (biotransformation, primarily in the liver) * **E**xcretion (elimination via kidneys or bile) **Analysis of Options:** * **Option A (Correct):** As defined above, pharmacokinetics tracks the concentration of a drug over time as it moves through various compartments. * **Option B (Incorrect):** This describes **Pharmacodynamics**, which is the study of the biochemical and physiological effects of drugs and their mechanisms of action (**"what the drug does to the body"**). * **Option C (Incorrect):** This refers to **Pharmacogenetics**, the study of how genetic variations influence individual responses to drugs (e.g., G6PD deficiency causing hemolysis with Primaquine). **NEET-PG High-Yield Pearls:** 1. **First-Pass Metabolism:** A key pharmacokinetic concept where a drug is metabolized (usually in the liver) before reaching systemic circulation, significantly reducing bioavailability (e.g., Nitroglycerin). 2. **Volume of Distribution (Vd):** A theoretical volume that relates the amount of drug in the body to its plasma concentration. Drugs with high Vd (like Digoxin) are sequestered in tissues and are not easily removed by hemodialysis. 3. **Half-life ($t_{1/2}$):** The time required for the plasma concentration to reduce by 50%. It takes approximately **4 to 5 half-lives** to reach a "steady state" or to completely eliminate a drug from the body.

Question 335: What is the half-life of digoxin?

A. 24 hours
B. 40 hours (Correct Answer)
C. 48 hours
D. 60 hours

Explanation: **Explanation:** **Correct Answer: B. 40 hours** Digoxin is a cardiac glycoside used primarily in the management of atrial fibrillation and heart failure. The half-life ($t_{1/2}$) of digoxin in a patient with normal renal function is approximately **36 to 40 hours**. This long half-life is a result of its extensive distribution into peripheral tissues (large volume of distribution) and its primary elimination via the kidneys through glomerular filtration and tubular secretion. **Analysis of Options:** * **A. 24 hours:** This is too short for digoxin. Drugs like Amiodarone (initial phase) or certain anticoagulants may fall in this range, but digoxin requires more time for plasma concentration to reduce by half. * **C & D. 48 and 60 hours:** While the half-life of digoxin can extend to **3–5 days (72+ hours)** in patients with **renal failure** (since it is 80% excreted unchanged in urine), 40 hours remains the standard physiological value for exam purposes. Digitoxin, a related glycoside, has a much longer half-life of 5–7 days. **High-Yield NEET-PG Clinical Pearls:** 1. **Steady State:** It takes approximately 4–5 half-lives to reach a steady state; for digoxin, this is roughly **7 days**. 2. **Therapeutic Window:** Digoxin has a narrow therapeutic index (0.5–2.0 ng/mL). Toxicity is common. 3. **Electrolyte Interactions:** **Hypokalemia**, hypomagnesemia, and hypercalcemia predispose a patient to digoxin toxicity. 4. **Antidote:** Digoxin-specific antibody fragments (**DigiFab**) are used for life-threatening toxicity. 5. **P-glycoprotein:** Digoxin is a substrate of P-gp; drugs like **Quinidine, Verapamil, and Amiodarone** inhibit P-gp, increasing digoxin levels and risk of toxicity.

Question 336: If the apparent volume of distribution of a drug exceeds the total body fluid volume, which of the following is the most likely reason?

A. The drug is sequestered in body tissues. (Correct Answer)
B. The drug is slowly eliminated from the body.
C. The drug is poorly soluble in plasma.
D. The drug is poorly bound to plasma proteins.

Explanation: **Explanation:** The **Apparent Volume of Distribution ($V_d$)** is a theoretical volume that relates the total amount of drug in the body to its concentration in the plasma ($V_d = \text{Total amount of drug} / \text{Plasma concentration}$). **1. Why Option A is correct:** If a drug is highly lipid-soluble or has a high affinity for specific tissues (e.g., adipose tissue, muscle, or bone), it leaves the vascular compartment and becomes **sequestered in tissues**. This results in an extremely low concentration of the drug in the plasma. Since $V_d$ is inversely proportional to plasma concentration, a very low plasma level yields a $V_d$ that exceeds the total body water (~42L). This indicates the drug is primarily stored outside the blood. **2. Why other options are incorrect:** * **Option B:** Elimination rate (half-life/clearance) describes how fast a drug leaves the body, not its anatomical distribution. * **Option C:** Poor plasma solubility might limit the dose administered, but $V_d$ specifically measures the ratio of distribution, not solubility limits. * **Option D:** If a drug is poorly bound to plasma proteins, more "free drug" is available to move into tissues, which *increases* $V_d$. However, the primary reason for a $V_d$ exceeding total body water is the active **tissue sequestration**, not just the lack of protein binding. **High-Yield Clinical Pearls for NEET-PG:** * **Digoxin:** Has a very high $V_d$ (~500L) because it binds strongly to cardiac and skeletal muscle. * **Chloroquine:** Has a massive $V_d$ (~13,000L) due to sequestration in the liver and retina. * **Hemodialysis:** Drugs with a high $V_d$ cannot be removed effectively by hemodialysis because most of the drug is hidden in tissues, not accessible in the blood. * **Loading Dose:** $V_d$ is the primary determinant used to calculate the loading dose ($LD = V_d \times \text{Target Plasma Concentration}$).

Question 337: Which of the following is NOT true about non-competitive inhibition?

A. Potency is reduced. (Correct Answer)
B. Km is unchanged.
C. Vmax is reduced.
D. Binds to a site other than the active site.

Explanation: ### Explanation In enzyme kinetics and pharmacodynamics, understanding the distinction between competitive and non-competitive inhibition is high-yield for NEET-PG. **Why Option A is the Correct Answer (The "NOT True" Statement):** In non-competitive inhibition, the inhibitor binds to an **allosteric site** (a site other than the active site). This reduces the total number of functional enzymes available, leading to a **decrease in Vmax** (maximum velocity). However, the affinity of the remaining functional enzymes for the substrate remains unchanged, meaning the **Km (Michaelis constant) is unchanged**. In pharmacology, **Potency** is determined by the **EC50** (or Km in enzyme terms). Since the Km remains constant, the potency of the drug is technically **unchanged**. Instead, non-competitive inhibition reduces **Efficacy** (represented by Vmax). Therefore, stating that "Potency is reduced" is incorrect. **Analysis of Incorrect Options:** * **B. Km is unchanged:** This is **true**. Since the inhibitor does not compete for the active site, the substrate's ability to bind to the enzyme (affinity) is not affected. * **C. Vmax is reduced:** This is **true**. Because the inhibitor effectively "takes enzymes out of commission" regardless of substrate concentration, the maximum reaction rate decreases. * **D. Binds to a site other than the active site:** This is **true**. This is the defining characteristic of non-competitive (allosteric) inhibition. **High-Yield Clinical Pearls for NEET-PG:** * **Competitive Inhibition:** Vmax stays the same, Km increases. Potency decreases (curve shifts right), Efficacy stays the same. (e.g., Statins, Methotrexate). * **Non-Competitive Inhibition:** Vmax decreases, Km stays the same. Efficacy decreases (curve shifts down), Potency stays the same. (e.g., Digoxin, Aspirin-cyclooxygenase binding). * **Irreversible Inhibition:** Often behaves kinetically like non-competitive inhibition because the enzyme is permanently sidelined.

Question 338: What are the mechanisms of drug transport through biological membranes?

A. Passive diffusion
B. Facilitated diffusion
C. Active transport
D. All of the above (Correct Answer)

Explanation: **Explanation:** Drug transport across biological membranes is a fundamental pharmacokinetic process that determines absorption, distribution, and excretion. The correct answer is **"All of the above"** because drugs utilize multiple pathways depending on their lipid solubility, molecular size, and charge. 1. **Passive Diffusion (Option A):** This is the most common mechanism (approx. 90% of drugs). It occurs along a concentration gradient without energy expenditure. Lipid-soluble drugs dissolve in the membrane lipoid matrix to pass through, while small water-soluble drugs pass through aqueous pores. 2. **Facilitated Diffusion (Option B):** This involves a specific carrier protein that helps "facilitate" the movement of a drug across the membrane. Like passive diffusion, it follows a concentration gradient and does not require ATP, but it is saturable and subject to inhibition. 3. **Active Transport (Option C):** This requires energy (ATP) to move drugs *against* a concentration gradient. It is mediated by specific transporters (e.g., P-glycoprotein). This process is vital for the renal and biliary excretion of many drugs and for transport across the blood-brain barrier. **High-Yield Clinical Pearls for NEET-PG:** * **Fick’s Law:** Governs passive diffusion; the rate of diffusion is directly proportional to the concentration gradient and lipid solubility. * **P-glycoprotein (P-gp):** An efflux transporter (active transport) that pumps drugs out of cells. It is a major cause of multi-drug resistance in cancer cells. * **Saturability:** Unlike passive diffusion, both facilitated diffusion and active transport are **saturable** processes because they rely on a finite number of carrier proteins. * **Ion Trapping:** Only the **unionized** form of a drug is lipid-soluble and can cross membranes easily. This is why acidic drugs (like Aspirin) are better absorbed in the acidic environment of the stomach.

Question 339: A 70 kg patient needs to be started on nitroglycerine (NTG) infusion. A 5 ml ampoule contains 5 mg/ml NTG. One ampoule is added to normal saline to make a total of 500 ml solution. Calculate the infusion rate if NTG is required at a rate of 10 mcg/min. (1 micro drip = 60 drops/ml)

A. 12 drops/min (Correct Answer)
B. 14 drops/min
C. 15 drops/min
D. 16 drops/min

Explanation: ### Explanation This question tests your ability to perform clinical drug calculations, a high-yield skill for NEET-PG. To solve this, follow a step-by-step approach: **1. Calculate the Total Amount of Drug:** * Ampoule volume = 5 ml; Concentration = 5 mg/ml. * Total NTG = 5 ml × 5 mg/ml = **25 mg**. **2. Determine the Concentration of the Infusion:** * Total solution volume = 500 ml. * Concentration = 25 mg / 500 ml = 0.05 mg/ml. * Convert to micrograms: 0.05 mg × 1000 = **50 mcg/ml**. **3. Calculate the Infusion Rate in ml/min:** * Required dose = 10 mcg/min. * Rate (ml/min) = Dose required / Concentration = 10 mcg/min ÷ 50 mcg/ml = **0.2 ml/min**. **4. Convert to Drops/min:** * Standard micro drip set = 60 drops/ml. * Infusion rate = 0.2 ml/min × 60 drops/ml = **12 drops/min**. --- ### Analysis of Options * **A (12 drops/min): Correct.** Derived from the precise calculation of concentration (50 mcg/ml) and flow rate. * **B, C, and D:** These are incorrect. They typically result from calculation errors, such as forgetting to multiply the ampoule volume by its concentration (using 5 mg total instead of 25 mg) or using a standard macro drip (15-20 drops/ml) instead of the specified micro drip. --- ### Clinical Pearls for NEET-PG * **Nitroglycerine (NTG):** A venodilator at low doses; causes arterial dilation at higher doses. * **Indication:** Acute Coronary Syndrome (ACS), Acute Decompensated Heart Failure, and Hypertensive Emergency. * **Pharmacokinetics:** NTG has a very short half-life (~1–3 minutes), necessitating continuous infusion. * **Storage Note:** NTG is adsorbed by PVC plastic; ideally, non-PVC administration sets should be used to ensure accurate delivery. * **Tachyphylaxis:** Continuous use leads to nitrate tolerance within 24 hours due to the depletion of free sulfhydryl groups.

Question 340: Succinylcholine is short-acting due to which of the following mechanisms?

A. Rapid excretion
B. Poor absorption
C. Rapid hydrolysis (Correct Answer)
D. None of the above

Explanation: **Explanation:** **Succinylcholine (Suxamethonium)** is a depolarizing neuromuscular blocking agent widely used for rapid sequence induction due to its quick onset and short duration of action (typically 5–10 minutes). **Why Rapid Hydrolysis is Correct:** The ultra-short duration of action is primarily due to its **rapid hydrolysis** by the enzyme **Pseudocholinesterase** (also known as Butyrylcholinesterase or Plasma Cholinesterase). Unlike acetylcholine, which is metabolized at the motor endplate by acetylcholinesterase, succinylcholine is metabolized in the plasma before it even reaches the neuromuscular junction and as it diffuses away from it. This rapid enzymatic breakdown ensures that only a small fraction of the injected dose actually reaches the nicotinic receptors. **Analysis of Incorrect Options:** * **A. Rapid excretion:** While drugs are eventually excreted by the kidneys, the termination of succinylcholine's effect happens far too quickly (within minutes) to be attributed to renal clearance. * **B. Poor absorption:** Succinylcholine is administered intravenously for emergency airway management, bypassing the absorption phase. Even when given intramuscularly, its short duration remains a function of metabolism, not absorption. **High-Yield Clinical Pearls for NEET-PG:** 1. **Succinylcholine Apnea:** Patients with a genetic deficiency or structural abnormality of pseudocholinesterase (atypical enzyme) cannot metabolize the drug quickly, leading to prolonged paralysis and respiratory apnea. 2. **Dibucaine Number:** This is a test used to detect atypical pseudocholinesterase. A low dibucaine number indicates abnormal enzyme activity. 3. **Phase II Block:** Prolonged or repeated administration of succinylcholine can lead to a "Phase II block," where the membrane repolarizes but remains desensitized, mimicking a non-depolarizing block. 4. **Side Effects:** Watch for hyperkalemia (especially in burn or trauma patients), muscle fasciculations, and malignant hyperthermia.

Practice by Chapter

Absorption and Bioavailability

Practice Questions

Drug Distribution and Protein Binding

Practice Questions

Biotransformation and Metabolism Pathways

Practice Questions

Renal and Non-renal Excretion

Practice Questions

Compartment Models

Practice Questions

Dose-Response Relationships

Practice Questions

Drug Efficacy and Potency

Practice Questions

Drug Tolerance and Tachyphylaxis

Practice Questions

Population Pharmacokinetics

Practice Questions

Pharmacokinetic Variability

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free